LLY
reports this Thursday. The drop in early March to test the bottom of the uptrend was a great opportunity. Now it's at all time high, showing bearish divergence, and has a history of price reversals after earnings releases. I'll be looking for updates on their pipeline management, monjaro production and growth, and progress toward Alzheimer treatment. The latter is high potential, but clinical trials in that space fail regularly.
I'll likely take a little profit before earnings and then re-accumulate to pullbacks to the
347
-356 range.